Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $45.00. The company’s shares closed yesterday at ...

PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...

Future of Healthcategory Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free November 13, 2024 ...

Baird analyst Joe Vruwink raised the firm’s price target on PTC (PTC) to $228 from $226 and keeps an Outperform rating on the shares. The firm said management was very forceful that disruption ...

Tampa Bay forecasters say it’s too early to tell where the storm will go, but urged residents to keep an eye on forecasts.

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.76 per share a year ago. These figures ...

2024 Future of Healthcategory US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder November 13, 2024 ...

Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Healthcare, Technology and Consumer Services sectors led shares lower. At the close in NYSE,... Investing.com ...

WARREN, N.J. (AP) — WARREN, N.J. (AP) — PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $106.7 million in its third quarter. The Warren, New Jersey-based company said it had a loss ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

The FBI said it is investigating the case but would not confirm to NBC News if they have information on whether the text messages originated in the country or overseas. A law enforcement source ...